Inclacumab has appeared to significantly reduce myocardial damage in certain types of acute and chronic myocardial infarction.372 In addition, the P-selectin has been identified as the independent risk factor for peripheral arterial disease and decreased ankle-brachial index.373 Though the basic principle indicates that P-selectin antagonist inclacumab is able to improve the development of peripheral artery disease, evidence from clinical studies is lacking.374. Here, SELP is linked to peripheral arterial disease.